Meagan Smith
Family Medicine · Carthage, TNNPI 1790211894
Payments from drug & device makers
Across 218 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$652
- AstraZeneca$441
- Pfizer$123
- Welch Allyn$108
- GSK$107
- plus $851 from 23 others
What the payments were for
- Food & beverage$3,33997%
- Other$1083%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 64 | $1,166 |
| AbbVie(2 entities) | 61 | $652 |
| AstraZeneca | 27 | $441 |
| Pfizer | 8 | $123 |
| Welch Allyn | 1 | $108 |
| GSK | 6 | $107 |
| Hologic Sales And Service, LLC | 5 | $100 |
| Lilly USA, LLC | 6 | $90 |
| Nestle Healthcare Nutrition Inc. | 5 | $83 |
| Corcept Therapeutics | 4 | $68 |
| Johnson & Johnson | 4 | $66 |
| Exact Sciences | 4 | $65 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $45 |
| Sumitomo Pharma America, Inc. | 3 | $35 |
| Boehringer Ingelheim | 2 | $32 |
| Eisai Inc. | 2 | $30 |
| Myriad Genetic Laboratories, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Redhill Biopharma Inc. | 2 | $24 |
| Lundbeck LLC | 1 | $19 |
| Baxter Healthcare | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Almatica Pharma LLC | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NONE$108
How this compares
$3,447 in reported general payments places this provider in the 75th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $80,025 |
| OzempicSemaglutide | 46 | $64,908 |
| MounjaroTirzepatide | 43 | $51,550 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 65 | $48,792 |
| JardianceEmpagliflozin | 41 | $42,759 |
| XareltoRivaroxaban | 58 | $37,064 |
| RybelsusSemaglutide | 23 | $27,276 |
| JanuviaSitagliptin Phosphate | 16 | $19,934 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $19,522 |
| MyrbetriqMirabegron | 18 | $16,047 |
| LinzessLinaclotide | 23 | $11,943 |
| FarxigaDapagliflozin Propanediol | 15 | $9,372 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $9,330 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $6,138 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $5,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,166 | $92,18469 claims |
| PfizerEliquis | $123 | $80,02572 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $441 | $63,314102 claims |
| Lilly USA, LLCMounjaro | $90 | $51,55043 claims |
| Boehringer IngelheimJardiance | $32 | $42,75941 claims |
| Johnson & JohnsonXarelto | $66 | $37,06458 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $107 | $28,85331 claims |
| MerckJanuvia | $15 | $19,93416 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $16,04718 claims |
| AbbVieLinzess, Synthroid | $652 | $14,39167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Carthage
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.